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Abstract
Background: Systemic Lupus erythematosus (SLE), also commonly referred to as lupus, is a rare, but sometimes, fatal
disease, that primarily affects young women. Lupus nephritis, a common manifestation of lupus, is more common and
more devastating in patients of minority race/ethnicity. Patients have negative views of immunosuppressive drugs for
lupus nephritis due to a concern about side effects and under-appreciation of its benefit. We designed a study to
assess the effectiveness of individualized, computerized patient decision-aid for immunosuppressive drugs for lupus
nephritis compared to a standard pamphlet for patient decision-making.
Methods: Adult women with lupus nephritis, with a current lupus nephritis flare or at risk of a future lupus nephritis flare
will be randomized to individualized, computerized patient decision-aid for immunosuppressive drugs vs. standard
pamphlet with information about lupus and its treatment including immunosuppressive drugs and outcomes. Patients
will complete outcome assessments immediately after the intervention has been administered. Patients will be followed
at 3-months with a brief survey, either in person or on the phone, and at 6-months with medical record review for
exploratory outcomes. Co-primary outcomes are decisional conflict and informed choice regarding immunosuppressive
drugs (combines values, knowledge and choice). Secondary outcomes include: (1) assessment of patient-physician
communication by assessing audio-taped physician-patient communication after intervention administration; (2)
concordance between patient’s desired and actual role in immunosuppressive drugs decision-making using the control
preference scale (CPS); and (3) patient perception of physician interaction using the interpersonal process of care- short
form (IPC-SF).
Discussion: This is one of the first studies to evaluate the effectiveness of an educational intervention targeting
minorities with lupus nephritis. This patient-centered lupus nephritis decision-aid will be available in the public domain
in English and Spanish.
Trial registration: ClinicalTrials.gov Identifier: NCT02319525; registered on November 5, 2014.
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Background
In the US, 161,000 individuals have definite SLE [1], making
it a rare disease with a prevalence of 0.05%. However, lupus
nephritis accounts for 2% of all end-stage renal disease in
the U.S. [2], a proof of its devastating effect on kidneys,
making it a serious disease. Compared to Whites, African-
Americans and Hispanics not only have a higher incidence
of lupus and higher associated mortality [3–6], but also a
higher prevalence of lupus nephritis and worse renal out-
come [6–14]. Thus, more research is needed in minorities
with lupus nephritis. Research in rare diseases is an area of
focus of patient-centered outcomes research institute
(PCORI) funding.
Many racial/ethnic minority patients do not receive
quality health care, due in part to lower health literacy
and numeracy [15], and poorer physician-patient com-
munication [16–19]. Compared to Caucasians, African-
American women with lupus have a lower likelihood of
accepting immunosuppressive drugs such as cyclophos-
phamide [20, 21]. Immunosuppressive drugs in combin-
ation with corticosteroids are the standard of care for
induction treatment of lupus nephritis treatment rather
than either medication alone; immunosuppressive drugs
are also important in the maintenance phase of the
treatment of lupus nephritis [22, 23].
There are many unanswered questions regarding the pa-
tient perception of immunosuppressive drugs in patients
with lupus, especially in minority patients with lupus. To
our knowledge, there is little or no evidence about whether
interventions to change patient knowledge or perception
regarding immunosuppressive drugs in lupus patients can
improve decision-making regarding these treatments. Com-
pared to Caucasians, studies show that African-Americans
had lower numeracy, which explained poor chronic disease
control in diabetes [24], and HIV medication regimen [25].
A decision-aid can provide information tailored to patients
with low health literacy and numeracy. Therefore, the
objective of this study is to compare the efficacy of the
usual education materials to individualized computerized
decision-aid (guide) to reduce the decision conflict regard-
ing treatment decisions for immunosuppressive therapies in
patients with lupus nephritis. Our long-term objective is to
improve outcomes in patients with lupus.
Methods
Study overview and hypothesis
Some patients with lupus have negative views of immuno-
suppressive drugs (cyclophosphamide, mycophenolate mofe-
til, azathioprine, calcineurin inhibitors such as cyclosporine
and tacrolimus etc.) and may reject consideration of these
drugs for treatment of their lupus [26–29]. The rejection of
immunosuppressive drugs may be related not on their
values, but also to limited knowledge of efficacy of these
drugs coupled with a fear of adverse events. As a result,
many patients choose to use only corticosteroids rather than
a combination of immunosuppressive drugs and corticoste-
roids, for the treatment of their active lupus nephritis. The
combination is not only more effective than corticosteroids
alone for lupus nephritis, but in many cases, may also be as-
sociated with similar or lower risk of adverse events [22, 23].
This study will test the effectiveness of a decision-aid re-
garding immunosuppressive drugs in patients with lupus
nephritis, with a focus on minority race/ethnicity. It is a
comparative effectiveness research (CER) study. The main
study aim is to assess the effectiveness of an individualized
computerized patient decision-aid focused on immunosup-
pressive drugs for lupus nephritis. Our hypotheses are that
in patients with lupus nephritis, compared to usual care
(educational pamphlet), individualized computerized
decision-aid will be more effective, as indicated by a greater
reduction in decisional conflict scores (Hypothesis 1) and a
higher rate of informed choice favoring immunosuppres-
sive drugs (concordance between values, knowledge and
choice of immunosuppressive drugs; Hypothesis 2).
The study protocol is registered at the clinicaltrials.gov
website, NCT02319525. All study visits, including
screening, baseline visit and 3-month follow-up assess-
ments will be done during patient’s regular scheduled
clinic visits/appointments, with few exceptions, if any.
This was done in order to keep the patient burden for
study participation low and to encourage patients with
lower socio-economic status and/or difficulty in trans-
portation to participate in this research study focused at
disadvantaged patients with limited resources.
Study design
This is a multicenter, parallel two-arm, prospective ran-
domized trial comparing an individualized computerized
decision-aid tool to an educational pamphlet (usual
care). Patients with lupus nephritis attending clinics at
the 4 recruiting sites will be recruited over a 2-year
period starting January 2015. Local Institutional Review
Board at each participating site, including the University
of Alabama at Birmingham (UAB), approved the study
procedures. This study was funded by a grant from the
Patient Centered Outcomes Research Institute (PCORI).
Study population
We will oversample African American and Hispanic
groups due to study’s focus on minorities, but other
racial groups will also be recruited in the study. Patients
with lupus nephritis will be enrolled from participating
clinics at UAB, University of California at San Francisco,
Baylor College of Medicine and Ohio State University.
These sites were chosen based on high numbers of
minority lupus patients, and a dedicated lupus clinic/ser-
vice at each site. We will recruit two groups of patients,
including patients with: (1) newly diagnosed active lupus
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nephritis needing immunosuppressive therapy or a lupus
nephritis flare despite current immunosuppressive therapy
requiring a change in immunosuppressive drug/therapy
(current lupus nephritis flare scenario); or (2) lupus neph-
ritis with prior experience and/or discussion regarding im-
munosuppressive therapy for a past lupus nephritis flare,
who are at the risk of a future lupus nephritis flare (future
lupus nephritis flare scenario). Decisional conflict and in-
formed choice were co-primary outcomes and secondary
outcomes included patient decision-making and patient-
physician communication.
Study intervention
The study intervention is an educational behavioral
intervention targeting patient knowledge and opinions
about immunosuppressive drugs. Active intervention
includes an individualized, computerized decision-aid,
developed specifically for this study, with a focus on
minority women. The control intervention is a pamphlet
with information about lupus and its treatment.
The decision-aid was developed in multiple steps in-
corporating the following elements: (1) comparative ef-
fectiveness data (benefits and common and uncommon
harms) on immunosuppressive drugs with systematic
reviews, meta-analysis and network meta-analysis (NMA)
incorporating evidence from direct comparison studies
and indirect comparisons [30–32]; (2) qualitative assess-
ment of patient barriers an facilitators to decision-making
regarding immunosuppressive medications [33, 34]; and
(3) iterative testing and modification of the decision-aid
by piloting in English- and Spanish speaking lupus
patients at multiple study sites to ensure that words,
phrases, messages and images used were acceptable and
could be easily understood considering health literacy,
numeracy and graphical literacy of the target population.
The decision-aid tool has been specifically designed in
English and Spanish to assist patients with lupus nephritis
make decisions regarding immunosuppressive drugs. The
decision-aid will provide individualized information about
immunosuppressive drugs specific to the each decision time
point (induction vs. maintenance). We developed this tool
for four probable scenarios based on the most common sce-
narios for a choice of immunosuppressive drugs (details in
the section below). The decision-aid for each scenario will
provide information about lupus in general, how lupus af-
fects kidneys, benefits and side effects of using corticoste-
roids, general information (medication formulation, route of
administration, costs of medication, dosage) and compara-
tive risks and benefits about two immunosuppressive being
compared, a final summary of the information provided and
reference to other patient support groups. Patients are
prompted to write down questions for their physician about
these choices. The computerized decision-aid is pro-
grammed such that once the scenario is chosen by the
coordinator per the guidance of the referring physician
based on the most likely two choices (or a provider in the
future), the decision-aid only shows that comparison.
Usual care or control group will receive a paper copy of
the American College of Rheumatology pamphlet with in-
formation on lupus nephritis which is freely available online
on the American College of Rheumatology website [35].
The pamphlet provides information about lupus in general,
causes of lupus, how lupus is diagnosed and treated,
broader health impact of lupus and living with lupus.
Study procedures
Screening
We will use International Classification of Diseases, ninth
revision, common modification (ICD-9-CM) code for
lupus, 710.0, to generate a list showing hospital clinic ap-
pointments of lupus nephritis patients, their gender and
race/ethnicity each month. We will screen this list to iden-
tify potentially eligible individuals weekly, and discuss each
patient’s potential eligibility for the study with the health
care provider for their lupus care, ahead of their visit
(Table 1, study eligibility criteria). We will also screen the
lists of patients scheduled for lupus clinics at each institu-
tion, since each participating institution has a weekly
lupus clinic. Male patients and patients with lupus but no
evidence of lupus nephritis will be excluded. In addition,
this study will be advertised in the rheumatology and
nephrology clinics, to rheumatology and nephrology fel-
lows and attending physicians, who frequently follow pa-
tients with lupus nephritis, and to renal pathologists at
each institution. The study coordinator will examine clinic
notes for eligibility criteria for patients referred to us by
physicians, fellows or renal pathologists. We will find out
the scheduled clinic appointments for these potentially
eligible patients, and inform their treating physician about
potential patient study enrollment on the day of the clinic
Table 1 Study eligibility criteria
Inclusion criteria
1. Females with lupus nephritis
2. Currently having a flare of lupus nephritis according to expert
rheumatologist and considering change or initiation of an
immunosuppressive medication for lupus nephritis (current flare)
or had had flare of lupus nephritis in the past and have had
experience or discussion of immunosuppressive medication for lupus
nephritis who were at risk for a future flare (future flare)
3. Age 18 years or older
4. All racial/ethnic groups
Exclusion Criteria
1. Male patients with lupus nephritis
2. Patients with lupus but no nephritis
3. Patients having kidney flare but medication change is not
considered
4. Patients with end stage renal disease on dialysis
5. Patients with a renal transplant or who are candidate for a renal
transplant
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visit. To ensure timely patient enrollment, we will have
regular meetings with rheumatology and nephrology
attending physicians and fellows who primarily provide
care to lupus patients, as well as send periodic emails to
all providers. A brief overview of the study flow is
provided in the CONSORT diagram (Fig. 1).
Baseline visit: procedures at initial patient visit
Physician Designation of the treatment scenario and
Informed Consent Before obtaining informed consent
from a study subject, the physician will be notified of the
potential recruitment and asked to assign a scenario
(medication group; details in the relevant section below)
and whether the patient having a flare of lupus nephritis
currently (current lupus nephritis flare scenario) or is at
risk of a flare in the future (future lupus nephritis flare
scenario). Study coordinator will then obtain a written
informed consent.
Randomization After informed consent is obtained,
subjects will be randomized using the Research Elec-
tronic Data Capture (REDCap) electronic data capture
tool [36]. Once the randomization form is completed
and saved, a unique participant identification number
will be generated. Randomization will be stratified by
study site and language (English vs. Spanish). Study coor-
dinators will enter patients’ name, date of birth, gender,
and recruitment site in the REDCap randomization form.
A computer-generated algorithm will randomize assign
study subjects to either decision-aid or pamphlet interven-
tion groups in a 1:1 ratio. We will use a separate unique
prefix for each site added to each patient identification
number in order to identify subjects by study site.
Pre-intervention assessment After each subject is ran-
domized, the study coordinator will administer assess-
ments of health literacy using Rapid Estimate of Adult
Literacy in Medicine-Short Form (REALM-SF) [37] and
Short Assessment of Health Literacy (SAHL) [38] and
graphical and numeric literacy to them. Study subjects
will also respond to questions assessing knowledge and
patient values about the immunosuppressive drugs for
lupus nephritis as treatment options for them (current
flare or future flare scenarios), and choose what treat-
ment they prefer now for their current (or future) lupus
nephritis flare. Pre-intervention assessments will evalu-
ate primary outcomes such as decisional conflict scale
[39] and patient’s choice of the immunosuppressive
drug based on knowledge and values related to taking
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primary and secondary outcomes
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3-month telephone and 6-month medical 
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Fig. 1 CONSORT diagram showing each stage of the randomized trial
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immunosuppressive drugs (informed choice; details in
the section on outcome measures below) [40, 41]. All
these assessments will be completed before administer-
ing the study intervention.
Intervention and scenarios Patients will read the educa-
tional material, i.e., decision-aid or the pamphlet, based on
the group they are randomized to, i.e., computerized
decision-aid or the pamphlet. This section provides details
of the intervention, and each intervention arm.
Decision-aid: In addition to the information on lupus
nephritis, the decision-aid will provide information on
four scenarios of choice between immunosuppressive
drugs. The scenarios were chosen by the patient’s lupus
care provider based on most likely choices for patient’s
treatment, based on either their current situation
(current flare) or anticipated future lupus nephritis flare
(future flare). Details are given below:
Scenario A (Treatment induction in immunosuppressive-
naive): This will be applicable to patients with newly diag-
nosed lupus nephritis or having history of lupus nephritis
with deteriorating renal function, who are currently not on
any immunosuppressive medication (current flare) or with
stable renal function currently not requiring immunosup-
pressive drug, but at the risk of future flare requiring induc-
tion therapy (future flare). The decision-aid tool for this
scenario will provide information about two medication
choices: cyclophosphamide (cytoxan) vs. mycophenolate
mofetil (cellcept).
Scenario B (Treatment maintenance in azathioprine fail-
ure): This will usually be applicable to patients with lupus
nephritis who are currently on azathioprine (Imuran) and
have deteriorating renal function (azathioprine failure;
current flare) or stable renal function on current azathio-
prine, but at the risk of future flare requiring change in
maintenance therapy (future flare). The decision-aid tool
for this scenario will provide information about two medi-
cation choices: cyclophosphamide (cytoxan) vs. mycophe-
nolate mofetil (cellcept).
Scenario C (Treatment maintenance in azathioprine
and mycophenolate mofetil failure): This will usually be
applicable to patients with lupus nephritis who have
failed azathioprine (Imuran) and mycophenolate mofetil
(cellcept) therapy and thus have signs of deteriorating
renal function (current flare) or stable renal function on
current immunosuppressive maintenance therapy, but at
the risk of future flare requiring change in maintenance
therapy (future flare). The decision-aid tool for this
scenario will provide information about two medication
choices: cyclophosphamide (cytoxan) vs. calcineurin
inhibitors (cyclosporine, tacrolimus etc.).
Scenario D (Treatment maintenance in mycophenolate
mofetil failure): This will usually be applicable to patients
with lupus nephritis who are currently on mycophenolate
mofetil (cellcept) and have deteriorating renal function
(cellcept failure; current flare) or stable renal function on
current mycophenolate mofetil maintenance therapy, but
at the risk of future flare requiring change in maintenance
therapy (future flare). The decision-aid tool for this
scenario will provide information about two medication
choices: cyclophosphamide (cytoxan) and azathioprine
(Imuran).
Pamphlet: This is a standard material available online
from the American College of Rheumatology (ACR) (3).
It will be provided as a paper pamphlet to the patient to
read and review. The pamphlet provides information
about lupus, symptoms of lupus, diagnosis of lupus, la-
boratory test for lupus and tips to control lupus in lay
language. It also provides web links to various support
groups for lupus.
Post-intervention assessment, including the Audio
taping of the physician-patient communication After
the administration of the intervention, patients will have a
discussion with physicians about immunosuppressive drugs
(only current flare patients) and all study subjects will
complete the post-intervention assessment questionnaire.
This questionnaire will measure co-primary outcomes (de-
cision conflict and informed choice) as in pre-intervention
assessments. In addition to this, the post-intervention ques-
tionnaire will measure two secondary outcomes, i.e., the
control preference scale (CPS) [42–44] and interpersonal
process of care- short form (IPC-SF) [45]. Patient-physician
conversation will be audio taped for all patients with
current lupus nephritis flares (current flare patients), but
not future flare patients, and assessed as a secondary
outcome. The audio taped conversation constitutes one of
the three secondary outcomes.
3-month phone vs. clinic follow-up assessment
At 3 months, study subjects will respond to the IPC ques-
tionnaire. Subjects will respond to this questionnaire via
phone or during a routine clinic visit, if it coincides with
study follow-up date. When subjects are not reachable via
phone and not seen in clinic, the study coordinator will
mail the follow up questionnaire.
6-month medical record follow-up assessment
The site study coordinators will extract laboratory, medi-
cation and other clinical data on exploratory outcomes at
6 months using Electronic Health Record (EHR) at each
study site for patients currently having lupus nephritis
flare (current flare scenario), except missed/cancelled out-
patient clinic visits which will be captured for all patients.
The exploratory outcomes include cumulative gluco-
corticoid dose, immunosuppressive medication adherence
and persistence, serum creatinine and spot protein/cre-
atinine ratios, and the number of missed/cancelled clinic
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appointments. We anticipate that due to the variation of
the frequency and type of regular laboratory assessments
of lupus nephritis across sites, there will be significant
amount of missing data. We also anticipate that available
laboratory data is likely to be collected at time points dif-
ferent from the 6-month study follow-up time-point, since
these are being done as part of clinical care not as part of
trial protocol, making it heterogeneous and sometimes
not usable. We will attempt to analyze these data as rigor-
ously as possible. We considered obtaining these data for
our study, but patient stakeholders advised us to not add
additional assessments or additional clinic or laboratory




Decisional Conflict Scale (DCS), low-literacy version: Deci-
sion conflict scale is a patient self-administered, validated
measure of decisional conflict, most commonly used as the
primary outcome in RCTs of decision-aid [46, 47]. We will
assess the change in decisional conflict related to immuno-
suppressive drugs after the administration of the interven-
tion at the baseline visit and compare the change from
baseline between the groups (Table 2). The low literacy
version consists of 10 items with 3 response categories (yes,
unsure, no) with overall score of 0 (no decisional conflict)
to 100 (extreme decisional conflict) [48]. Responses are
given the following score values: yes = 0; unsure = 2; no = 4.
Ten items are summed and multiplied by 2.5 to provide a
score ranging 0-100. It is available in English and Spanish
versions. Decisional conflict represents a state of uncer-
tainty about a choice or course of action and is more likely
in situations involving high-stakes choices with important
potential gains and losses, value tradeoffs in selecting a
choice or a course of action (vs. the alternative) or uncer-
tain outcomes. The DCS scale also has 4 subscales: (1) Un-
certainty subscore: Scores range from 0 (feels extremely
certain about best choice) to 100 (feels extremely uncertain
about best choice); (2) Informed subscore: Scores range
from 0 (feels extremely informed) to 100 (feels extremely
uninformed); (3) Values Clarity subscore: Scores range from
0 (feels extremely clear about personal values for benefits
and risks/side effects) to 100 (feels extremely unclear about
personal values for benefits and risks/side effects); and (4)
Support subscore: Scores range from 0 (feels extremely
supported in decision making) to 100 (feels extremely un-
supported in decision making). DCS subscale scores will be
explored, if data are available for comparisons.
Informed choice We will assess informed choice by using
a validated multidimensional model of informed choice
[40, 41] that individually assesses and then combines three
constructs: values regarding immunosuppressive drugs,
knowledge about immunosuppressive drugs, and treatment
choices. We will assess informed choice after patient has
viewed the decision-aid or lupus pamphlet at the baseline
study visit before any treatment decision-making. Values
will be assessed with a list consisting of patients’ views
regarding immunosuppressive drugs as treatment option
and their side effects generated by us based on patient con-
cerns about regarding immunosuppressive drugs. The
values statements consisted of both positive and negative
values about immunosuppressive drugs, mixed in a ran-
dom order, with responses ranging from strongly disagree
to strongly agree. We will score positive and negative value
statements with appropriate signs (+ or -) and aggregate
into a total score. A higher total score will indicate more
positive values regarding using immunosuppressive drugs
and a median score (or an overall more positive vs. more
negative values) will be used to classify values as positive
vs. negative regarding using immunosuppressive drugs.
Knowledge regarding immunosuppressive drugs for lupus
nephritis were assessed using 20 questions and considered
“adequate knowledge” if patients answer at least 75% of
questions correctly. Choice will be assessed based on
response to a single item on a nominal scale with anchors
of start vs. don’t start immunosuppressives and “uncertain”
Table 2 Study Outcomes and Outcome measures
Co-Primary outcomes/ Time of assessment Description
Change in Decisional Conflict Scale
(DCS) score [39, 46–48, 64]/Baseline post-intervention
10-item patient-reported scale for lower literacy populations with 3-level response
categories
Informed choice [40, 41]/Baseline
post-intervention
Concordance between patient’s values related to taking immunosuppressive drugs and
patients’ decision to start immunosuppressive drugs in those with adequate knowledge
about immunosuppressive drugs
Secondary outcomes
Control Preferences Scale [51]/Baseline
post-intervention
2-item patient-reported assessment of whether the decision-making concordant with patient's
preference about their role
Interpersonal Processes of Care [45]/Baseline
post-intervention
18-item patient-reported multidimensional measure of physician-patient communication
Audiotaped Patient-physician
discussion [56]/Baseline post-intervention
Active Patient Participation Coding Scheme decoding speech acts indicating patient
participation and whether physician communication was patient-centered
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in the middle and 15 circles, asking patient’s choice in
response to a question “if your doctor asked you right now
to make a choice about immunosuppressives, please show
where you would be on the scale below by choosing a circle
below”. Informed choice refers to a choice that is based on
accurate knowledge and is concordant with one’s values. A
higher proportion indicates more patients with informed
choice regarding immunosuppressive drugs.
Secondary outcome measures
Control preferences Scale This validated measure will
assess patient participation in decision-making for patients
with lupus nephritis flare (current flare scenario patients
only). This assesses how much decision-making control
patients would like to have versus actually experienced by
each patient. It determines the correlation between patient
satisfaction with care and discriminates between those who
feel involved in the decision versus not [42–44]. There are
5 responses for 5 control options: active, active shared, col-
laborative, passive shared and passive, which will be catego-
rized as active (combining active and active shared),
collaborative and passive (combining passive and passive
shared), as previously [49–51]. We will examine for con-
cordance between desired and actual roles played by pa-
tients with lupus nephritis flare (current flare scenario). A
higher concordance in roles (desired vs. actually played) in-
dicates that more patients experienced the desired role in
decision-making.
Patient physician communication and care processes
This will be assessed using the Interpersonal Processes
of Care Short Form (IPC-SF), an 18-item validated
patient-reported measure of patient-physician communi-
cation and care processes [45, 52–55]. IPC-SF is avail-
able in both English and Spanish versions.
Analysis of Audiotaped physician-patient interaction
This will be done recording the patient physician discus-
sion about immunosuppressive drugs and using the Active
Patient Participation Coding Scheme (APPC), a validated
instrument to assess indicators and facilitators of patient
participation [56], for patients with a current lupus neph-
ritis flare (current flare scenario). Three types of speech
acts will be coded as active patient participation, because
of their potential to influence a doctor’s behavior as well
as the content and structure of the consultation [57–60],
namely, question-asking, assertive responses, and expres-
sions of concern. In addition, physician communication
will be coded using speech acts such as supportive talk
and partnership building. Trained coders will transcribe
and recognize active participation with ‘utterance’ as the
unit of analysis (the oral analogue of a simple sentence,
independent clause), which will be summed for each
interaction to create a frequency of the degree of active
participation.
Exploratory outcome measures
We will assess the following exploratory outcomes,
where data are available. Most exploratory outcomes are
applicable only to patients with current flare scenarios,
except missed/cancelled appointments (current flare or
future flare scenario). Outcomes include cumulative
glucocorticoid dose, medication adherence and persist-
ence with immunosuppressive drugs, renal function as
assessed by spot protein/creatinine ratios, serum creatin-
ine, 24-h proteinuria, proportion with complete or par-
tial renal remission, number of missed or cancelled
clinic appointments.
We will also assess the acceptability of study interven-
tion using an acceptability survey [61], as in previous
studies [62]. Patients will rate the quality and the quan-
tity of the information presented in decision aids (4-
point scale ranging from “excellent” to “poor”) and rate
the appropriateness of amount of information (re-
sponder burden), presentation style and usefulness.
Feasibility will be assessed by the amount of assistance
required in navigating decision aids (none, a little, some,
a lot) and with a self-administered satisfaction question-
naire [63]. Patients will rate satisfaction with decision
aids on a 5-point Likert scale ranging from strongly
agree to strongly disagree: Easy to use, practical, process




Our study has an adequate power to assess the treat-
ment effect for the co-primary outcomes, with an
estimated enrollment of 200 patients. We anticipate
that 100 African-American and 100 Hispanic/Cauca-
sian females will lupus nephritis be enrolled in the
trial. Allowing 10% loss to follow-up, this sample size
will provide 80% power for co-primary outcomes. We
will be able to detect a moderate effect size difference be-
tween group means on decisional conflict (range 0–100)
using a two sample t-test and two tailed type I error rate
of 0.05 (hypothesis 1) [48, 64] and a 15% absolute
difference in the proportion of patients with informed
choice using a one-sided type I error rate of 0.05 (hy-
pothesis 2) [65].
Analysis of outcomes measures
We will compare demographic variables and baseline
characteristics between decision-aid and pamphlet groups,
including health, numeric and graphical literacy by compar-
ing mean values or proportions as appropriate. Measures of
variability (standard deviation) will be calculated. We will
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compare primary and secondary outcome measures using
Student t test or analysis of variance or comparison of
proportions. A two-sided p-value < 0.05 will be considered
significant. We will stratify variables based on language
(English/Spanish) and study sites and compare these
variables using chi-square test or Fisher’s exact test. All
statistical analyses will be carried out using SAS, v9.4 (Cary,
NC). We will also use logistic or linear regression to assess
other predictors of each of the co-primary outcomes,
including the intervention.
Study limitations
Our study has several limitations. We are assessing two
co-primary outcomes. We chose these two co-primary
outcomes, since they capture two complimentary aspects
of decision-making, related to our intervention, an indi-
vidualized decision-aid. If our intervention, an individual-
ized decision-aid, is found to be effective, we will not
know as to which individual component/message, led to
the reduction in decision conflict or more informed
choice. However, this is not a critical question to answer
at this time, since as an educational intervention, our
decision-aid is easy to implement. Since our decision-aid
will be available in public domain, it would be available for
any patient to use, and can be further modified to be con-
textually relevant. Another limitation is that while we have
the decision aid and outcome instruments in English and
Spanish, we do not have translations in other languages.
This can be done in the future, and will make this
decision-aid even easier to use for lupus patients who
speak languages other than English and Spanish. In order
to reduce the patient burden, we will not assess patient
satisfaction and quality of life in this study. Therefore, the
effect of this decision-aid on these domains will need to
be examined in future studies.
Discussion
This study is a 2-arm parallel group trial of a behavioral pa-
tient educational intervention on patient decision-making
in women with lupus nephritis, with a focus on minority
race/ethnicity. Decision-making for immunosuppressive
medications is a challenge in the treatment of patients with
lupus nephritis, especially in racial minorities, who have
more severe disease and worse outcomes. Previous studies
have shown that there are both knowledge gaps related to
immunosuppressive drugs as well as patient views that do
not favor the use of immunosuppressive medications in
lupus nephritis [26–29]. To our knowledge, there are no
trials of educational or behavioral interventions and few
studies of interventions in minority patients with lupus
nephritis, if any. Therefore, our study that investigates if a
patient-centered, individualized, easy to use intervention
can reduce conflict in patient decisions and improve patient
decision-making regarding immunosuppressive drugs for
lupus nephritis, will fill an important knowledge gap.
Conclusion
In conclusion, by its focus on the minority lupus patients
who deal with a life-threatening complex illness with se-
vere morbidity at a young age, our study results will pave
the way for other studies of computerized patient
decision-aid not only in lupus nephritis, but also for
other similar complex illnesses (common and rare) with
significant morbidity and mortality risk. This decision-
aid will be in the public domain, available free of charge
to everyone, for a free online download.
Trial status
The study is ongoing. We are currently following patients
enrolled at the four study sites.
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